Abstracts tagged "gout"

Abstract Number: 405 • 2013 ACR/ARHP Annual Meeting
Gout and RA: Not Such a Rare Coexistence After All
Christina Petsch¹, Elizabeth Araujo¹, Matthias Englbrecht¹, Axel J. Hueber², Georg Schett¹, Bernhard Manger¹ and Juergen Rech², ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: According to the current rheumatology literature, the simultaneous occurrence of rheumatoid arthritis (RA) and gout is rare and only a few cases have been…
Abstract Number: 1816 • 2012 ACR/ARHP Annual Meeting
Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
Kim Coley¹, Melissa Saul² and Karen Pater¹, ¹Pharmacy & Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gout is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints and soft tissues. The overall prevalence is increasing…
Abstract Number: 162 • 2012 ACR/ARHP Annual Meeting
Metabolic Syndrome: The Genesis of Nephrolithiasis in Gout Patients
Filipi M. Mello¹, Rafael B. Tomita², Ricardo Fuller³, Marco Antonio G. P. Filho², Thiago B. M. Barros⁴, Leandro L. do Prado², Kristopherson L. Augusto² and Claudia Goldenstein-Schainberg⁵, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Rheumatology Division - University of São Paulo, São Paulo, Brazil, ³Reumatologia, Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Reumatologia Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Rheumatology Division - University of São Paulo, São Paulo, Brazil
Background/Purpose: Gout patients have a high frequency of metabolic syndrome (MS), a disorder known to be associated with hyperinsulinemia. The latter condition augments proximal tubular…
Abstract Number: 2043 • 2012 ACR/ARHP Annual Meeting
Documentation of Improvement Over 2 Months in Osteoarthritis, Systemic Lupus Erythematosus, Spondyloarthropathy and Gout Similarly to Rheumatoid Arthritis According to Function, Pain, Patient Global Estimate and RAPID3 On a Multidimensional Health Assessment Questionnaire (MDHAQ)
Isabel Castrejón¹, Martin J. Bergman² and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Taylor Hospital, Ridley Park, PA
Background/Purpose: The health assessment questionnaire (HAQ) and multidimensional HAQ (MDHAQ) were developed initially to assess patients with rheumatoid arthritis (RA). The most feasible method to…
Abstract Number: 1632 • 2012 ACR/ARHP Annual Meeting
Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties
Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, Biology, Metabolex, Inc., Hayward, CA
Background/Purpose: In most patients with gout, elevated serum urate is linked to excess uric acid reabsoprtion in the proximal renal tubule by anion transporters/exchangers, including…
Abstract Number: 163 • 2012 ACR/ARHP Annual Meeting
Evaluating Allopurinol Therapy and Serum Uric Acid Levels in Medicare Beneficiaries with Gout
Melea Ward¹, Anthony M. Louder², Keith A. Szymanski³ and Leonardo Tamariz⁴, ¹Competitive Health Analytics, Louisville, KY, ²Competitive Health Analytics, Inc., Louisville, KY, ³Takeda Pharmaceuticals America, Inc., Deerfield, IL, ⁴University of Miami, Miami, FL
Background/Purpose: Higher serum uric acid levels in gout patients have been associated with an increased frequency and risk of gout flares and greater subsequent healthcare…
Abstract Number: 2045 • 2012 ACR/ARHP Annual Meeting
Treatment Patterns and Monitoring of Serum Uric Acid Levels in a Large Cohort of Gout Patients in the United States: Is There Room for Improvement?
Yong Chen¹, Kasem S. Akhras², Michael Grabner¹, Rima H. Tawk³ and Ralph Quimbo¹, ¹HealthCore, Inc., Wilmington, DE, ²Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ³Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Currently, there are no guidelines in the United States on monitoring serum uric acid (sUA) levels in gout and gout treatment patterns. However, there…
Abstract Number: 1633 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Add-On Therapy to Allopurinol 300mg Lowers Hypoxanthine and Xanthine Plasma Levels in a Dose-Dependent Fashion: Results From a 12-Week Randomized Controlled Trial in Patients with Gout
Shanta Bantia¹, Leigh Harman², Cynthia Parker¹, Damon Papac³, Andreas Maetzel⁴, Brian Taubenheim⁴ and Alan S. Hollister⁴, ¹Discovery Biology, BioCryst Pharmaceuticals, Inc., Durham, NC, ²Bioanalytical Chemistry, BioCryst Pharmaceuticals, Inc., Durham, NC, ³Bioanalytical Sciences, Southern Research Institute, Birmingham, AL, ⁴Development, BioCryst Pharmaceuticals, Inc., Durham, NC
Background/Purpose: Ulodesine (BCX4208) is an oral, once-daily, purine nucleoside phosphorylase (PNP) inhibitor in clinical development as add-on therapy for the chronic management of hyperuricemia in…
Abstract Number: 139 • 2012 ACR/ARHP Annual Meeting
Lack of Effect of Supplemental Vitamin C On Serum Urate in Patients with Gout
Lisa K. Stamp¹, Christopher Frampton¹, John L. O'Donnell², Jill Drake³ and Peter T. Chapman⁴, ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, ³Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁴Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: The key to effective long-term management of gout is sustained reduction of serum urate (SU) Methods: Patients with gout and a SU >0.36mmol/L…
Abstract Number: 2037 • 2012 ACR/ARHP Annual Meeting
Poor Quality of Gout Care Is Strongly Associated with Higher Gout-Related Health Care Utilization
Jasvinder A. Singh¹ and Joshua Richman², ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Biostatistics, UAB School of Medicine, Birmingham, AL
Background/Purpose: Proponents of improving quality of gout care have suggested various gout quality indicators, but no study to date has shown the link between…
Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Robert Terkeltaub¹, Robert R. Evans², Steven P. Weinstein³, Richard Wu⁴ and H. Ralph Schumacher⁵, ¹Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ²Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]
Abstract Number: 140 • 2012 ACR/ARHP Annual Meeting
Patients That Continue to Flare Despite Apparent Optimal Urate Lowering Therapy
Dinesh Khanna¹, Puja Khanna², David Hagerty³, Chris Storgard⁴, Robert Mischler⁵ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Medical, Ardea Bioscience, San Diego, CA, ⁴4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis and its worldwide prevalence is increasing. The purpose of this study is to describe physician, patient and treatment…
Abstract Number: 1901 • 2012 ACR/ARHP Annual Meeting
Chronic Gout. Improvement According to Outcome Meaures in Rheumatology Domains in Daily Clinical Practice
Janitzia Vazquez-Mellado¹, Betsabé Serrano¹, Jaime Mendoza², Sergio Garcia-Mendez¹, V.Chantal Hernández¹, Virginia Pascual Ramos³, Ruben Burgos-Vargas¹ and Marina Rull-Gabayet², ¹Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Dept de Immunología y Reumato, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: OMERACT has proposed domains to evaluate the effect of treatment in patients with acute and chronic gout. Their frequency, time to improve and percentage…
Abstract Number: 815 • 2012 ACR/ARHP Annual Meeting
Exploratory Analysis of Radiographic Change in Patients Treated with Intensive Urate-Lowering Therapy
Nicola Dalbeth¹, Anthony Doyle², Fiona M. McQueen³, John S. Sundy⁴ and Herbert S. B. Baraf⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁴Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ⁵Arthritis & Rheumatism Associates, Wheaton, MD
Background/Purpose: In patients with gout, tophi are strongly associated with radiographic damage. Effective urate-lowering therapy (ULT) reduces tophus size. However, no studies to date have…
Abstract Number: 143 • 2012 ACR/ARHP Annual Meeting
Proposed Gout Treatment Guidelines and Meeting Serum Urate and Flare Goals
Jasvinder A. Singh¹, David Hagerty², Chris Storgard³, Robert Mischler⁴ and Robert Morlock⁴, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Medical, Ardea Bioscience, San Diego, CA, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Bioscience, San Diego, CA
Background/Purpose: Although gout is a relatively common condition, treatment is often not ideal with many patients continuing to experience multiple flares and some developing complications…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.